Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE).
Lee CK, Liao BC, Subramaniam S, Chiu CH, Mersiades AJ, Ho CC, Brown C, Lai CL, Hughes BGM, Yang TY, O'Byrne K, Luo YH, Yip S, Ho CL, Bray V, Su WC, Moore M, Feng WL, Bai YY, Ford K, Cummins MM, Stockler MR, Solomon BJ, John T, Chih-Hsin Yang J.
Lee CK, et al. Among authors: bai yy.
JTO Clin Res Rep. 2024 Nov 22;6(2):100771. doi: 10.1016/j.jtocrr.2024.100771. eCollection 2025 Feb.
JTO Clin Res Rep. 2024.
PMID: 39877028
Free PMC article.